Ravgen

Ravgen is a private, commercial-stage diagnostics company with a proprietary platform for enriching fetal DNA from maternal blood samples, enabling non-invasive prenatal testing (NIPT). The company's primary offerings include tests for Down syndrome, other chromosomal abnormalities, single-gene disorders, and prenatal paternity, all aimed at providing safer alternatives to invasive procedures. Led by founder and CEO Dr. Ravinder Dhallan, Ravgen has published foundational research in top-tier journals and appears to generate revenue through its testing services and potential partnerships. Its strategic position leverages a growing global NIPT market but faces significant competition from larger, established players.

Proprietary method for enriching fetal cell-free DNA from maternal blood using a preservative-based sample preparation to increase the fetal DNA fraction for analysis.

Ravgen operates in the highly competitive NIPT market dominated by large players like Natera, Illumina (via its spin-out), Roche, and others. Its differentiation lies in its proprietary fetal DNA enrichment technology and a test menu that includes single-gene disorders and very early prenatal paternity.